Song Chen to lead research group in Cellular Genetics Programme
This new group will develop powerful, cutting-edge technologies to map individual cells in the brain and other tissues, to understand how they form
The Wellcome Sanger Institute is delighted to welcome Song Chen as its latest Faculty member. His research will focus on mapping cells in the brain and other tissues using single-cell methods, to determine how each type of cell forms, what it does, and how it contributes to the developing tissue. He will also study brain diseases such as cancers using organoid models.
Song joins the Wellcome Sanger Institute from the University of California San Diego, and is aiming to understand the range of different cell types in tissues, especially the brain. Developing powerful single-cell multi-omics technologies to map the cells in healthy and diseased brains, he is exploring the molecular pathways involved in normal brain development and that of tumours. This could then allow the design of targeted molecular and cellular therapies.
“I’m fascinated by how complex tissues such as the brain are created, and understanding how the different cells communicate with each other to control this growth. My research focuses on the development of novel high-throughput single-cell sequencing technologies to help answer this key question in biology. The Welcome Sanger Institute is renowned for its ability to conduct cutting-edge science at huge scale, and I’m extremely pleased to be joining them.”
Dr Song Chen, Group Leader at the Wellcome Sanger Institute
Before joining the Sanger Institute, Song developed novel single-cell sequencing technologies at the University of California San Diego, USA. These allowed, for the first time, the ability to resolve cellular diversity and cell-type specific control pathways in defined regions of the human brain. He also developed a high-throughput sequencing method that could integrate both the transcriptome and epigenetic data from developing and adult mouse brain cells. This paved the way for assembling multi-dimensional cell atlases of various human organs.
At the Sanger Institute, Song is establishing a team of genome biologists, cell biologists and bioinformaticians to develop both dry-lab single-cell multi-omics sequencing methods, and wet-lab CRISPR and organoid models. They will aim to build an atlas of epigenomic, transcriptomic, and proteomics data during various stages of normal organ development and disease progression in brain, kidney and other tissues.
“I am delighted that Song will be leading a new research team in the Sanger’s Cellular Genetics Programme. He is developing cutting-edge single cell multi-omics methods which will be invaluable for uncovering how cells interact with each other to create different tissues. This will also contribute towards the global Human Cell Atlas initiative, which is aiming to map every cell type in the body, to understand health and disease.”
Two Postdoctoral roles are currently available in Song’s team. For more information please visit https://jobs.sanger.ac.uk/vacancy/postdoctoral-fellow-x2-cellular-genetics-426036.html
The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast – we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog.
Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.
11 May 2021
Identifying the rise of multi-drug resistant E.coli
Largest genomic study of E.coli has tracked the rise of multi-drug resistance (MDR) in Norway.
30 Apr 2021
New genetic target for blood cancer treatment
Researchers have identified a vulnerability in some cases of acute myeloid leukaemia that could be harnessed for targeted treatment of these ...